The role of BMI1 in endometrial cancer and other cancers

Yiting Zhao & Xiaofeng Jin et al. · 2022-12-20

9Citations
Endometrial cancer (EC) is the third leading gynecological malignancy, and its treatment remains challenging. B cell-specific Moloney murine leukemia virus integration site-1 (BMI1) is one of the core members of the polycomb group (PcG) family, which plays a promoting role in the occurrence and development of various tumors. Notably, BMI1 has been found to be frequently upregulated in endometrial cancer (EC) and promote the occurrence of EC through promoting epithelial-mesenchymal transition (EMT) and AKT/PI3K pathways. This review summarizes the structure and upstream regulatory mechanisms of BMI1 and its role in EC. In addition, we focused on the role of BMI1 in chemoradiotherapy resistance and summarized the current drugs that target BMI1.
Journal
Gene
TL;DR

The structure and upstream regulatory mechanisms of BMI1 and its role in endometrial cancer are summarized and the role of BMI 1 in chemoradiotherapy resistance is focused on and the current drugs that target BMI1 are summarized.

AI-generated by Semantic Scholar

Authors
Yiting Zhao, Weili Yang, Kaifeng Zheng, Jun Chen, Xiaofeng Jin